Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CUE NASDAQ:ERNA NASDAQ:PYXS NASDAQ:SNTI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCUECue Biopharma$35.00-2.0%$254.22$4.97▼$41.42$115.75M2.371.95 million shs243,028 shsERNAErnexa Therapeutics$7.53-3.7%$5.89$3.18▼$100.46$9.12M1.883.75 million shs1.45 million shsPYXSPyxis Oncology$2.74+21.2%$1.59$0.97▼$5.55$142.05M1.43497,531 shs1.90 million shsSNTISenti Biosciences$0.99+0.1%$0.94$0.77▼$3.88$30.68M2.09227,258 shs58,311 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCUECue Biopharma0.00%+142.40%-85.50%-87.60%-94.76%ERNAErnexa Therapeutics0.00%+111.92%+42.18%-16.87%-89.93%PYXSPyxis Oncology0.00%+32.94%+53.74%+49.67%+112.21%SNTISenti Biosciences0.00%+6.51%+15.61%+5.89%-70.33%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCUECue Biopharma$35.00-2.0%$254.22$4.97▼$41.42$115.75M2.371.95 million shs243,028 shsERNAErnexa Therapeutics$7.53-3.7%$5.89$3.18▼$100.46$9.12M1.883.75 million shs1.45 million shsPYXSPyxis Oncology$2.74+21.2%$1.59$0.97▼$5.55$142.05M1.43497,531 shs1.90 million shsSNTISenti Biosciences$0.99+0.1%$0.94$0.77▼$3.88$30.68M2.09227,258 shs58,311 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCUECue Biopharma0.00%+142.40%-85.50%-87.60%-94.76%ERNAErnexa Therapeutics0.00%+111.92%+42.18%-16.87%-89.93%PYXSPyxis Oncology0.00%+32.94%+53.74%+49.67%+112.21%SNTISenti Biosciences0.00%+6.51%+15.61%+5.89%-70.33%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCUECue Biopharma 1.00SellN/AN/AERNAErnexa Therapeutics 2.00Hold$30.00298.41% UpsidePYXSPyxis Oncology 2.63Moderate Buy$6.83149.39% UpsideSNTISenti Biosciences 2.80Moderate Buy$8.50762.24% UpsideCurrent Analyst Ratings BreakdownLatest SNTI, ERNA, PYXS, and CUE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/7/2026ERNAErnexa TherapeuticsBrookline Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$30.005/5/2026PYXSPyxis Oncology WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$6.004/21/2026ERNAErnexa Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/21/2026SNTISenti Biosciences Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/30/2026SNTISenti Biosciences Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$13.00 ➝ $11.003/27/2026CUECue Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)3/24/2026PYXSPyxis Oncology Stifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$9.00 ➝ $8.003/24/2026PYXSPyxis Oncology HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$7.00(Data available from 5/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCUECue Biopharma$27.47M4.13N/AN/A$10.08 per share3.47ERNAErnexa Therapeutics$580K15.19N/AN/A$7.64 per share0.99PYXSPyxis Oncology$13.86M12.42N/AN/A$0.86 per share3.19SNTISenti Biosciences$20K1,534.89N/AN/A$0.21 per share4.69Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCUECue Biopharma-$26.60M-$9.61N/AN/AN/A-96.85%-165.19%-77.77%N/AERNAErnexa Therapeutics-$14.08M-$75.47N/AN/AN/AN/A-1,262.77%-228.54%N/APYXSPyxis Oncology-$79.62M-$1.29N/AN/AN/AN/A-101.77%-69.81%5/21/2026 (Estimated)SNTISenti Biosciences-$61.44M-$3.19N/AN/AN/AN/A-301.48%-90.03%N/ALatest SNTI, ERNA, PYXS, and CUE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2026Q1 2026PYXSPyxis Oncology-$0.35N/AN/AN/A$10.94 millionN/A3/27/2026Q4 2025SNTISenti Biosciences-$0.43-$0.53-$0.10-$0.53$1.00 million$0.02 million3/23/2026Q4 2025PYXSPyxis Oncology-$0.35-$0.29+$0.06-$0.29$0.13 million$11.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCUECue BiopharmaN/AN/AN/AN/AN/AERNAErnexa TherapeuticsN/AN/AN/AN/AN/APYXSPyxis OncologyN/AN/AN/AN/AN/ASNTISenti BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCUECue BiopharmaN/A2.742.74ERNAErnexa TherapeuticsN/A1.011.01PYXSPyxis OncologyN/A3.413.41SNTISenti BiosciencesN/A1.671.67Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCUECue Biopharma35.04%ERNAErnexa Therapeutics70.55%PYXSPyxis Oncology39.07%SNTISenti Biosciences25.70%Insider OwnershipCompanyInsider OwnershipCUECue Biopharma1.82%ERNAErnexa Therapeutics1.50%PYXSPyxis Oncology10.60%SNTISenti Biosciences3.12%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCUECue Biopharma603.24 million3.18 millionOptionableERNAErnexa Therapeutics101.17 million1.15 millionNo DataPYXSPyxis Oncology6062.85 million56.19 millionOptionableSNTISenti Biosciences431.14 million30.17 millionNot OptionableSNTI, ERNA, PYXS, and CUE HeadlinesRecent News About These CompaniesSenti Biosciences (SNTI) Expected to Announce Earnings on TuesdayMay 3, 2026 | americanbankingnews.comSenti Biosciences to Present on Logic-Gated Cell Therapies in Educational Session at AACR Annual Meeting 2026April 13, 2026 | markets.businessinsider.comSenti Biosciences to Present on Logic-Gated Cell Therapies in Educational Session at AACR Annual Meeting 2026April 13, 2026 | globenewswire.comSenti Biosciences Announces Publication in Cell Systems Demonstrating Advanced Logic-Gated CAR Design for Cell TherapiesApril 1, 2026 | globenewswire.comSenti Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate UpdateMarch 27, 2026 | globenewswire.comSenti Biosciences to Present Clinical and Translational Data on SENTI-202 at the 11th Annual Innate Killer ConferenceMarch 23, 2026 | globenewswire.comSenti Biosciences Amends Lease, Restructures GeneFab SubleaseMarch 19, 2026 | tipranks.comSenti Biosciences to Present at Leerink Partners 2026 Global Healthcare ConferenceMarch 3, 2026 | tmcnet.comSenti Biosciences to Present at Leerink Partners 2026 Global Healthcare ConferenceMarch 3, 2026 | globenewswire.comSenti Biosciences to Showcase Gene Circuit Technology and Partnership Opportunities at TD Cowen Health Care ConferenceFebruary 24, 2026 | quiverquant.comQSenti Biosciences to Present at TD Cowen 46th Annual Health Care ConferenceFebruary 24, 2026 | globenewswire.comSenti Bio Participates in Cell & Gene Live Event Highlighting Cutting-Edge Technologies Advancing Cell Therapy DevelopmentFebruary 20, 2026 | globenewswire.comSenti Biosciences Completes Enrollment in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)February 11, 2026 | globenewswire.comSenti Biosciences Selected for On-Stage Presentation at Healthcare Conference Taipei 2026February 3, 2026 | globenewswire.comSenti Biosciences Participates in Virtual Investor CEO Connect Segment to Discuss the Company’s Groundbreaking AML Data at the American Society of Hematology Annual Meeting ...January 21, 2026 | uk.finance.yahoo.comSenti Biosciences Participates in Virtual Investor CEO Connect Segment to Discuss the Company's Groundbreaking AML Data at the American Society of Hematology Annual Meeting and ...January 14, 2026 | tmcnet.comSenti Biosciences, Inc. Highlights FDA RMAT Designation for SENTI-202 in Virtual Investor CEO Connect SegmentJanuary 14, 2026 | quiverquant.comQSenti Biosciences Participates in Virtual Investor CEO Connect Segment to Discuss the Company's Groundbreaking AML Data at the American Society of Hematology Annual Meeting and Recently Granted RMAT DesignationJanuary 14, 2026 | globenewswire.comSenti Bio to Participate in Panel Presentation at Biotech Showcase Alongside the J.P. Morgan Annual Healthcare ConferenceJanuary 9, 2026 | globenewswire.comSenti Biosciences Announces New Employment Inducement GrantsDecember 18, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesThis 4/20, Wall Street Is Betting on More Than MarijuanaBy Jeffrey Neal Johnson | April 20, 20263 Low-Volatility ETFs for Peace of Mind in Turbulent TimesBy Nathan Reiff | April 13, 2026RPM International's Blowout Quarter Sparks a 15% Rally By Thomas Hughes | April 10, 2026TPG Built a Record Year, Then Lost 40%—Is the Selloff Overdone? By Peter Frank | April 16, 20263 European Bank Stocks Nearing New 52-Week HighsBy Dan Schmidt | April 27, 2026SNTI, ERNA, PYXS, and CUE Company DescriptionsCue Biopharma NASDAQ:CUE$35.00 -0.73 (-2.04%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$34.15 -0.85 (-2.43%) As of 05/8/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.Ernexa Therapeutics NASDAQ:ERNA$7.53 -0.29 (-3.71%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$7.35 -0.18 (-2.42%) As of 05/8/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.Pyxis Oncology NASDAQ:PYXS$2.74 +0.48 (+21.24%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$2.53 -0.21 (-7.81%) As of 05/8/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.Senti Biosciences NASDAQ:SNTI$0.99 +0.00 (+0.07%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$0.99 +0.00 (+0.32%) As of 05/8/2026 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/04 - 05/08 SoundHound’s Bottom Is In—Inflection and 50% Upside Ahead? Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus AppLovin Pops After Earnings With Growth Catalysts in Sight Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
